BPTH - BIO-PATH HOLDINGS INC
Previous close
1.11
0.070 6.306%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:25:16 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$1.04
0.07
6.73%
Fundamental analysis
22%
Profitability
18%
Dept financing
3%
Liquidity
50%
Performance
25%
Performance
5 Days
-17.46%
1 Month
29.26%
3 Months
13.18%
6 Months
-50.48%
1 Year
105.05%
2 Year
-96.09%
Key data
Stock price
$1.11
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.50 - $12.00
52 WEEK CHANGE
-$89.90
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Peter H. Nielsen
Region: US
Website: biopathholdings.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: biopathholdings.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. The company develops products based on DNAbilize, a drug delivery and antisense technology.
Recent news